Cerus Announces the Inclusion of Pathogen Reduction Technology in FDA’s Revised Guidance Document on Bacterial Safety Standards for Platelets

FREE Breaking News Alerts from StreetInsider.com!

E-mail Address

StreetInsider.com Top Tickers, 6/25/2026

1. QCOM
2. MU
3. FDX
4. CBRS
5. USO
6. SPY
7. HTZ
8. KBH
9. HON
10. JPM

Go back to Cerus Announces the Inclusion of Pathogen Reduction Technology in FDA’s Revised Guidance Document on Bacterial Safety Standards for Platelets

FBR Capital Reiterates Outperform on Cerus (CERS) Following FDA Approval

March 16, 2016 10:18 AM EDT

FBR Capital reiterated an Outperform rating and $10.00 price target on Cerus (NASDAQ: CERS) following the FDA's approval of INTERCEPT for the treatment of platelets suspended in 100% plasma.

Analyst Thomas Yip commented, "Earlier this morning, Cerus Corporation announced that the FDA has approved INTERCEPT for the... More